Connect with us

Hi, what are you looking for?

Jewish Business News

VC, Investments

Israeli Pain Monitoring Startup Medasense Raises $18 Million

Imagine being unable to communicate at the time when doctors most need to know what is going on inside of your head.

Medasense Monitoring Device from Website

Israeli med-tech startup Medasense raised $18 million in a Series B round of funding. Sabadell Asabys venture capital firm (Asabys Partners, Spain), Israeli family offices, Baxter Ventures, Olive Tree Ventures and LGL Capital were all part of the investment. Startup Nation seems to be wasting no time at the start of the new Jewish year 5781.

Medasense technology is the developer of an exclusive technology that objectively monitors and quantifies the patient’s pain response level using artificial intelligence algorithms and a proprietary noninvasive sensor platform. This new technology, which is currently used in operating rooms and critical care settings, where patients are under anesthesia and unable to communicate, enables clinicians to personalize treatment: control pain, avoid overdose, and eliminate doubt. The company has also been active in the implementation of its technology on COVID-19 ventilated patients.

So now we have new med-tech which can literally feel your pain. Imagine being unable to communicate at the time when doctors most need to know what is going on inside of your head. This can be either during an operation or when someone is unconscious after suffering an injury or an accident. So Startup Nation continues to be at the forefront of med tech.


“Together with our trusted investors, who share our passion to improve pain management, we expect to make a significant contribution to enhancing pain care,” said Galit Zuckerman-Stark, Medasense founder and CEO. “This funding round will allow us to expand and further consolidate commercial deployment of NOL technology in Europe through our distribution agreement with Medtronic and to complete the process of obtaining FDA approval for commercialization in the U.S.”

Josep Ll. Sanfeliu, founding partner of Asabys Partners, stated: “Medasense is a model startup, having successfully introduced a disruptive medical device technology to the market. Its artificial intelligence solution is impacting clinical outcomes to benefit patients and to enable better use of healthcare resources.”

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Newsletter

Advertisement

You May Also Like

World News

In the 15th Nov 2015 edition of Israel’s good news, the highlights include:   ·         A new Israeli treatment brings hope to relapsed leukemia...

empty

The contract signed between the Israeli government and Pfizer shows clearly and unequivocally that this is a clinical study on humans - The agreement...

Travel

After two decades without a rating system in Israel, at the end of 2012 an international tender for hotel rating was published.  Invited to place bids...

Business

Now Platika joins and elite club of $10 billion plus Israeli firms.

Advertisement